Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

96 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and safety of CT-P47 versus reference tocilizumab: 32-week results of a randomised, active-controlled, double-blind, phase III study in patients with rheumatoid arthritis, including 8 weeks of switching data from reference tocilizumab to CT-P47.
Smolen JS, Trefler J, Racewicz A, Jaworski J, Zielińska A, Krogulec M, Jeka S, Wojciechowski R, Kolossa K, Dudek A, Krajewska-Włodarczyk M, Hrycaj P, Klimiuk PA, Burmester GR, Kim S, Bae Y, Yang G, Jung Y, Hong J, Keystone E. Smolen JS, et al. Among authors: jeka s. RMD Open. 2024 Oct 18;10(4):e004514. doi: 10.1136/rmdopen-2024-004514. RMD Open. 2024. PMID: 39424404 Free PMC article. Clinical Trial.
A phase 3, randomized, double-blind, active-controlled clinical trial to compare BAT1806/BIIB800, a tocilizumab biosimilar, with tocilizumab reference product in participants with moderate-to-severe rheumatoid arthritis with inadequate response to methotrexate: treatment period 2 analysis (week 24 to week 48).
Leng X, Leszczyński P, Jeka S, Liu S, Liu H, Miakisz M, Gu J, Kilasonia L, Stanislavchuk M, Yang X, Zhou Y, Dong Q, Mitroiu M, Addison J, Rezk MF, Zeng X. Leng X, et al. Among authors: jeka s. Arthritis Res Ther. 2024 Sep 7;26(1):157. doi: 10.1186/s13075-024-03375-w. Arthritis Res Ther. 2024. PMID: 39244595 Free PMC article. Clinical Trial.
Environmental and Genetic Determinants of Ankylosing Spondylitis.
Bilski R, Kamiński P, Kupczyk D, Jeka S, Baszyński J, Tkaczenko H, Kurhaluk N. Bilski R, et al. Among authors: jeka s. Int J Mol Sci. 2024 Jul 17;25(14):7814. doi: 10.3390/ijms25147814. Int J Mol Sci. 2024. PMID: 39063056 Free PMC article. Review.
Comparing tocilizumab biosimilar BAT1806/BIIB800 with reference tocilizumab in patients with moderate-to-severe rheumatoid arthritis with an inadequate response to methotrexate: a phase 3, randomised, multicentre, double-blind, active-controlled clinical trial.
Leng X, Leszczyński P, Jeka S, Liu SY, Liu H, Miakisz M, Gu J, Kilasonia L, Stanislavchuk M, Yang X, Zhou Y, Dong Q, Rezk M, Mitroiu M, Addison J, Zeng X. Leng X, et al. Among authors: jeka s. Lancet Rheumatol. 2024 Jan;6(1):e40-e50. doi: 10.1016/S2665-9913(23)00237-0. Lancet Rheumatol. 2024. PMID: 38258678 Clinical Trial.
Real-World Effectiveness and Safety of SDZ ETN, an Etanercept Biosimilar, in Patients with Rheumatic Diseases: Final Results from Multi-Country COMPACT Study.
Schmalzing M, Kellner H, Askari A, De Toro Santos J, Vazquez Perez-Coleman JC, Foti R, Jeka S, Haraoui B, Allanore Y, Peichl P, Oehri M, Rahman M, Furlan F, Romero E, Hachaichi S, Both C, Brueckmann I, Sheeran T. Schmalzing M, et al. Among authors: jeka s. Adv Ther. 2024 Jan;41(1):315-330. doi: 10.1007/s12325-023-02706-8. Epub 2023 Nov 11. Adv Ther. 2024. PMID: 37950790 Free PMC article.
96 results